- Report
- January 2026
- 199 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP
- Report
- January 2026
- 186 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP
- Report
- January 2026
- 185 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP
- Report
- August 2026
- 197 Pages
Global
From €5248EUR$5,850USD£4,486GBP
- Report
- August 2026
- 177 Pages
Global
From €5248EUR$5,850USD£4,486GBP
- Report
- February 2026
- 250 Pages
Global
From €4028EUR$4,490USD£3,443GBP
- Report
- February 2026
- 250 Pages
Global
From €4028EUR$4,490USD£3,443GBP
- Report
- February 2026
- 250 Pages
Global
From €4028EUR$4,490USD£3,443GBP
- Report
- February 2026
- 250 Pages
Global
From €4028EUR$4,490USD£3,443GBP
- Report
- February 2026
- 250 Pages
Global
From €4028EUR$4,490USD£3,443GBP
- Report
- February 2026
- 250 Pages
Global
From €4028EUR$4,490USD£3,443GBP
- Report
- February 2026
- 250 Pages
Global
From €4028EUR$4,490USD£3,443GBP
- Report
- May 2026
- 140 Pages
Global
From €4261EUR$4,750USD£3,643GBP
- Report
- April 2026
- 100 Pages
Global
From €4261EUR$4,750USD£3,643GBP
- Report
- September 2025
- 142 Pages
Global
From €3500EUR$4,180USD£3,097GBP
- Report
- September 2025
- 87 Pages
Global
From €3500EUR$4,180USD£3,097GBP
- Report
- August 2020
- 250 Pages
Saudi Arabia
From €3229EUR$3,600USD£2,761GBP
- Report
- February 2023
- 130 Pages
France
From €2234EUR$2,490USD£1,910GBP
- Report
- August 2025
- 150 Pages
Global
From €5337EUR$5,950USD£4,563GBP
- Report
- September 2024
- 110 Pages
Global
From €5337EUR$5,950USD£4,563GBP

Empagliflozin is a medication used to treat type 2 diabetes, a condition in which the body does not produce enough insulin or does not use insulin properly. It belongs to a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, which work by blocking the reabsorption of glucose in the kidneys, allowing it to be excreted in the urine. This helps to lower blood sugar levels. Empagliflozin is also used to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
Empagliflozin is marketed by several pharmaceutical companies, including Boehringer Ingelheim, Eli Lilly, and Merck. It is available in tablet form and is taken once daily. It is also available in combination with other diabetes medications, such as metformin and linagliptin. Show Less Read more